Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Vireo Health International

CNSX:VREO
Snowflake Description

Mediocre balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
VREO
CNSX
CA$72M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Vireo Health International Inc. operates in cannabis industry in the United States. The last earnings update was 94 days ago. More info.


Add to Portfolio Compare Print
  • Vireo Health International has significant price volatility in the past 3 months.
VREO Share Price and Events
7 Day Returns
-29.8%
CNSX:VREO
-13.8%
CA Pharmaceuticals
-6.2%
CA Market
1 Year Returns
-
CNSX:VREO
-65.6%
CA Pharmaceuticals
-2%
CA Market
VREO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Vireo Health International (VREO) -29.8% -41.4% -43.3% - - -
CA Pharmaceuticals -13.8% -22.6% -20.7% -65.6% 0.8% 283%
CA Market -6.2% -5% -2.8% -2% 0.6% 8.9%
1 Year Return vs Industry and Market
  • No trading data on VREO.
  • No trading data on VREO.
Price Volatility
Industry
5yr Volatility vs Market

VREO Value

 Is Vireo Health International undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Vireo Health International. This is due to cash flow or dividend data being unavailable. The share price is CA$0.85.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Vireo Health International's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Vireo Health International's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:VREO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $-0.25
CNSX:VREO Share Price ** CNSX (2020-02-28) in CAD CA$0.85
CNSX:VREO Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.745 $0.63
Canada Pharmaceuticals Industry PE Ratio Median Figure of 11 Publicly-Listed Pharmaceuticals Companies 14.69x
Canada Market PE Ratio Median Figure of 509 Publicly-Listed Companies 14.76x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Vireo Health International.

CNSX:VREO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:VREO Share Price ÷ EPS (both in USD)

= 0.63 ÷ -0.25

-2.56x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vireo Health International is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Vireo Health International is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Vireo Health International's expected growth come at a high price?
Raw Data
CNSX:VREO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.56x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 1.38x
Canada Market PEG Ratio Median Figure of 246 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Vireo Health International, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Vireo Health International's assets?
Raw Data
CNSX:VREO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $1.18
CNSX:VREO Share Price * CNSX (2020-02-28) in CAD CA$0.85
CNSX:VREO Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.745 $0.63
Canada Pharmaceuticals Industry PB Ratio Median Figure of 154 Publicly-Listed Pharmaceuticals Companies 1.28x
Canada Market PB Ratio Median Figure of 2,345 Publicly-Listed Companies 1.31x
CNSX:VREO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:VREO Share Price ÷ Book Value per Share (both in USD)

= 0.63 ÷ 1.18

0.54x

* Primary Listing of Vireo Health International.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vireo Health International is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Vireo Health International's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Vireo Health International has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

VREO Future Performance

 How is Vireo Health International expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
78.1%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is Vireo Health International expected to grow at an attractive rate?
  • Unable to compare Vireo Health International's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Vireo Health International's earnings growth to the Canada market average as no estimate data is available.
  • Vireo Health International's revenue growth is expected to exceed the Canada market average.
Annual Growth Rates Comparison
Raw Data
CNSX:VREO Future Growth Rates Data Sources
Data Point Source Value (per year)
CNSX:VREO Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 78.1%
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 69.4%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 39.9%
Canada Market Earnings Growth Rate Market Cap Weighted Average 9.8%
Canada Market Revenue Growth Rate Market Cap Weighted Average 4.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:VREO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:VREO Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 155 2
2020-12-31 94 2
2020-02-29
2019-12-31 31 2
CNSX:VREO Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 27 -19 -21
2019-06-30 24 -15 -6
2019-03-31 21 -10 -4
2018-12-31 18 -9 -3
2018-09-30 16 -6 -2
2017-12-31 11 -1 0
2016-12-31 4 -4 6

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Vireo Health International is high growth as no earnings estimate data is available.
  • Vireo Health International's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:VREO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Vireo Health International Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:VREO Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31
2020-12-31
2020-02-29
2019-12-31
CNSX:VREO Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 -0.25
2019-06-30 -0.08
2019-03-31 -1.46
2018-12-31 -2.55
2018-09-30 -1.14
2017-12-31 -0.41
2016-12-31 5.58

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Vireo Health International will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Vireo Health International's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Vireo Health International has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

VREO Past Performance

  How has Vireo Health International performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Vireo Health International's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Vireo Health International does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Vireo Health International's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Vireo Health International's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Vireo Health International's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Vireo Health International Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:VREO Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 26.59 -21.07 20.66
2019-06-30 23.52 -6.49 15.42
2019-03-31 20.56 -4.49 12.09
2018-12-31 18.46 -3.08 11.91
2018-09-30 16.10 -1.62 8.94
2017-12-31 10.87 -0.43 6.19
2016-12-31 4.26 5.80 3.96

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Vireo Health International has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Vireo Health International has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Vireo Health International improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Vireo Health International's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Vireo Health International has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

VREO Health

 How is Vireo Health International's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Vireo Health International's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Vireo Health International is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Vireo Health International's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Vireo Health International's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 14.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Vireo Health International Company Filings, last reported 4 months ago.

CNSX:VREO Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 100.58 4.08 16.36
2019-06-30 112.20 3.99 30.34
2019-03-31 109.28 1.43 40.40
2018-12-31 41.65 1.01 9.62
2018-09-30 38.48 1.01 15.21
2017-12-31 27.49 1.01 2.60
2016-12-31 28.11 0.03 2.09
  • Vireo Health International's level of debt (4.1%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Vireo Health International's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Vireo Health International has less than a year of cash runway based on current free cash flow.
  • Vireo Health International has less than a year of cash runway if free cash flow continues to grow at historical rates of 45.1% each year.
X
Financial health checks
We assess Vireo Health International's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Vireo Health International has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

VREO Dividends

 What is Vireo Health International's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Vireo Health International dividends.
If you bought CA$2,000 of Vireo Health International shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Vireo Health International's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Vireo Health International's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:VREO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.9%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.7%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2.1%
Canada Top 25% Dividend Yield 75th Percentile 5.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

CNSX:VREO Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2020-02-29
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Vireo Health International has not reported any payouts.
  • Unable to verify if Vireo Health International's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Vireo Health International's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Vireo Health International has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Vireo Health International's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Vireo Health International afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Vireo Health International has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

VREO Management

 What is the CEO of Vireo Health International's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Kyle Kingsley
COMPENSATION $252,248
AGE 41
CEO Bio

Dr. Kyle Kingsley MD is the Founder, Chairman of the Board and CEO of Vireo Health International Inc. He served as the CEO of Minnesota Medical Solutions LLC until August 2018. Dr. Kingsley is a board-certified emergency medicine physician and founder of Vireo Health LLC, and Minnesota Medical Solutions LLC, a wholly-owned subsidiary of Vireo Health. Dr. Kingsley has been the Chairman of the Board at Minnesota Medical Solutions LLC since 2019. Dr. Kingsley has dedicated his work life to the refinement of the Vireo Health cannabis-derived medicine model, a system that focuses on patient care, sound medicine, excellent operations and vigorous science. Dr. Kingsley is co-author of the Medical Cannabis Primer for Healthcare Providers, which was written for physicians and other healthcare providers to improve cannabis-derived medicine education and understanding in the medical community.

CEO Compensation
  • Kyle's compensation has increased whilst company is loss making.
  • Kyle's remuneration is higher than average for companies of similar size in Canada.
Management Team Tenure

Average tenure and age of the Vireo Health International management team in years:

0.3
Average Tenure
43
Average Age
  • The average tenure for the Vireo Health International management team is less than 2 years, this suggests a new team.
Management Team

Kyle Kingsley

TITLE
Founder
COMPENSATION
$252K
AGE
41

Amber Shimpa

TITLE
Chief Administrative Officer & Director
COMPENSATION
$272K
AGE
39
TENURE
0.2 yrs

Ari Hoffnung

TITLE
Chief Strategy Officer & Director
COMPENSATION
$311K
AGE
44
TENURE
0.3 yrs

Stephen Dahmer

TITLE
Chief Medical Officer
COMPENSATION
$320K
AGE
43
TENURE
3.5 yrs

Bruce Linton

TITLE
Executive Chairman
AGE
53

Shaun Nugent

TITLE
Chief Financial Officer
TENURE
0.2 yrs

Christian Gonzalez

TITLE
Executive Vice President of Operations
TENURE
0.3 yrs

Eric Greenbaum

TITLE
Chief Science Officer
AGE
39

Sam Gibbons

TITLE
Vice President of Investor Relations
TENURE
1.1 yrs

Michael Schroeder

TITLE
General Counsel & Chief Compliance Officer
AGE
50
Board of Directors Tenure

Average tenure and age of the Vireo Health International board of directors in years:

0.8
Average Tenure
46
Average Age
  • The average tenure for the Vireo Health International board of directors is less than 3 years, this suggests a new board.
Board of Directors

Kyle Kingsley

TITLE
Founder
COMPENSATION
$252K
AGE
41

Amber Shimpa

TITLE
Chief Administrative Officer & Director
COMPENSATION
$272K
AGE
39

Ari Hoffnung

TITLE
Chief Strategy Officer & Director
COMPENSATION
$311K
AGE
44

Bruce Linton

TITLE
Executive Chairman
AGE
53
TENURE
0.3 yrs

Amy Langer

TITLE
Independent Director
AGE
46
TENURE
0.8 yrs

Chelsea Grayson

TITLE
Independent Director
AGE
47
TENURE
0.8 yrs

Judd Nordquist

TITLE
Independent Director
AGE
48
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
26. Mar 19 Buy Chad Martinson Individual 19. Mar 19 19. Mar 19 13,820 CA$4.79 CA$66,170
X
Management checks
We assess Vireo Health International's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Vireo Health International has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

VREO News

Simply Wall St News

We Think Vireo Health International (CNSX:VREO) Can Stay On Top Of Its Debt

CNSX:VREO Historical Debt, August 15th 2019 A Look At Vireo Health International's Liabilities The latest balance sheet data shows that Vireo Health International had liabilities of US$8.75m due within a year, and liabilities of US$28.4m falling due after that. … This surplus suggests that Vireo Health International has a conservative balance sheet, and could probably eliminate its debt without much difficulty. … Vireo Health International may have net cash on the balance sheet, but it is still interesting to look at how well the business converts its earnings before interest and tax (EBIT) to free cash flow, because that will influence both its need for, and its capacity to manage debt.

Simply Wall St -

Did Vireo Health International Inc. (CNSX:VREO) Insiders Buy Up More Shares?

As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.' Check out our latest analysis for Vireo Health International The Last 12 Months Of Insider Transactions At Vireo Health International Over the last year, we can see that the biggest insider purchase was by Director Chad Martinson for CA$66k worth of shares, at about CA$4.79 per share. … CNSX:VREO Recent Insider Trading, July 11th 2019 Insider Ownership of Vireo Health International For a common shareholder, it is worth checking how many shares are held by company insiders. … Our data suggests Vireo Health International insiders own 1.6% of the company, worth about CA$3.7m.

Simply Wall St -

VREO Company Info

Description

Vireo Health International Inc. operates in cannabis industry in the United States. It engages in the cultivation, production, and sale of medical cannabis products to company owned and third party dispensaries. The company sells and distributes a suite of products through dispensaries, home delivery, and wholesale channels. The company is headquartered in Minneapolis, Minnesota.

Details
Name: Vireo Health International Inc.
VREO
Exchange: CNSX
Founded:
CA$72,464,343
85,252,169
Website: http://www.vireohealth.com
Address: Vireo Health International Inc.
MoZaic East Building,
4th Floor,
Minneapolis,
Minnesota, 55408,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX VREO Subordinate Voting Shares Canadian National Stock Exchange CA CAD 20. Mar 2019
OTCPK VREO.F Subordinate Voting Shares Pink Sheets LLC US USD 20. Mar 2019
DB 0ZF1 Subordinate Voting Shares Deutsche Boerse AG DE EUR 20. Mar 2019
Number of employees
Current staff
Staff numbers
400
Vireo Health International employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/02/29 03:09
End of day share price update: 2020/02/28 00:00
Last estimates confirmation: 2019/11/29
Last earnings filing: 2019/11/27
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.